Clinical Trials
15 trialsNCT07296484 2026-05-12
CAPTAIN-T2D
Sparrow Pharmaceuticals
Phase 2 Recruiting
NCT03604198 2026-04-21
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
Corcept Therapeutics
Phase 2 Active not recruiting
NCT07247162 2025-12-10
LINC CARE
RECORDATI GROUP
Phase 4 Not yet recruiting
NCT05307328 2025-10-08
RESCUE
Sparrow Pharmaceuticals
Phase 2 Completed
NCT04308590 2025-09-04
GRADIENT
Corcept Therapeutics
Phase 3 Completed
NCT03697109 2025-07-16
GRACE
Corcept Therapeutics
Phase 3 Completed
NCT05804669 2025-04-10
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
Crinetics Pharmaceuticals Inc.
Phase 1/2 Recruiting
NCT04373265 2024-02-23
Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)
Corcept Therapeutics
Phase 1 Completed
NCT05347979 2023-02-09
Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants
Corcept Therapeutics
Phase 1 Completed
NCT02468193 2020-05-06
Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome
Novartis
Phase 2 Completed
NCT02804750 2019-10-15
Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
Corcept Therapeutics
Phase 2 Completed
NCT00422201 2019-10-11
Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion
HRA Pharma
Phase 2 Terminated
NCT00936741 2014-04-02
An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Corcept Therapeutics
Phase 3 Completed
NCT01371565 2014-03-18
Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
Corcept Therapeutics
Phase 3 Completed
NCT00569582 2013-08-22
SEISMIC
Corcept Therapeutics
Phase 3 Completed